Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Offices

China
Building C14, 218 Xinghu St.
Suzhou Industrial Park
215123, CHN
Suzhou Industrial Park, CHN

Funding

TOTAL $25M
FUNDING TOTAL $25M
Series B, 11/2012
Lilly Asia Ventures
Fidelity Biosciences
Fidelity Growth Partners Asia
$25M

Tags

Innovent Biologics

Innovent Biologics, Inc. is a privately held biopharmaceutical company that is dedicated to the development and manufacturing of monoclonal antibodies to be marketed in China and elsewhere around the world.

Innovent is funded by the venture arm of Fidelity, which is a major investment firm in the US, Lilly Ventures, and Suzhou bioBay. The registered capital is 30Million US Dollars. The founders and senior management team of Innovent have over 70 years of combined work experience in the discovery, development and manufacture of biologics in the US, Europe and worldwide and were involved in the launch of such products as Bexxar, Conbercept, Natrecor, Oncorine, Recombivax HB, and others.

Recent Milestones

Videos

Screenshots

Innovent Biologics screenshot
Above: Innovent Biologics
Uploaded: 11/21/12

Sources

  1. Innovent Biologics Adds $25 Million to Expand its Antibody Pipeline and its Manufacturing Capabilities (fiercepharmamanufacturing.com) [edit]
Edit This Page
Last Edited 8/28/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy